Aureka Biotechnologies raises $100M Series B

Aureka develops AI-powered digital biology platforms for discovering protein therapeutics and antibody treatments. The company announced a $100M Series B on August 10, 2026, from its base in Laguna Hills, US. Investors and valuation were not disclosed in Crunchbase's round record; Lounge adds them as they are reported. It has raised more than $100M in total venture funding.

0Share to feed

Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.

See plans →Log in

Discussion · 0

Create a free account to join the discussion.

Every AI deal, decoded — free for members

Members get unlimited reads, can save and upvote, and see who else is building in the same space. Launch beta: free accounts created before Oct 20 get every paid feature — 82 of 100 slots left.

Create your free account Log in